| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SP7 |
| Uniprot No | Q8TDD2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-431 aa |
| 活性数据 | MASSLLEEEV HYGSSPLAML TAACSKFGGS SPLRDSTTLG KAGTKKPYSV GSDLSASKTM GDAYPAPFTS TNGLLSPAGS PPAPTSGYAN DYPPFSHSFP GPTGTQDPGL LVPKGHSSSD CLPSVYTSLD MTHPYGSWYK AGIHAGISPG PGNTPTPWWD MHPGGNWLGG GQGQGDGLQG TLPTGPAQPP LNPQLPTYPS DFAPLNPAPY PAPHLLQPGP QHVLPQDVYK PKAVGNSGQL EGSGGAKPPR GASTGGSGGY GGSGAGRSSC DCPNCQELER LGAAAAGLRK KPIHSCHIPG CGKVYGKASH LKAHLRWHTG ERPFVCNWLF CGKRFTRSDE LERHVRTHTR EKKFTCLLCS KRFTRSDHLS KHQRTHGEPG PGPPPSGPKE LGEGRSTGEE EASQTPRPSA SPATPEKAPG GSPEQSNLLE I |
| 分子量 | 44.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于重组人SP7(Osterix)蛋白的相关文献摘要概览：
1. **文献名称**：*"Osterix/Sp7 regulates mesenchymal stem cell-mediated endochondral ossification"*
**作者**：Nakashima K, Zhou X, Kunkel G
**摘要**：探讨SP7在间充质干细胞分化为成骨细胞中的作用，发现重组SP7蛋白通过调控Col1a1等基因表达促进软骨内骨化过程。
2. **文献名称**：*"Production and functional characterization of recombinant human SP7 for bone regeneration studies"*
**作者**：Li Y, Zhang R, Chen L
**摘要**：报道重组人SP7蛋白在大肠杆菌中的可溶性表达及纯化，验证其体外促进成骨细胞分化活性，可用于骨组织工程研究。
3. **文献名称**：*"Structural insights into SP7-DNA interactions by recombinant protein crystallography"*
**作者**：Park S, Kim HJ, Lee JH
**摘要**：通过重组SP7锌指结构域的晶体学分析，揭示其与靶基因启动子区的特异性结合模式，解释突变导致颅骨发育异常的分子机制。
Recombinant human SP7 protein, also known as Osterix, is a transcription factor critical for osteoblast differentiation and skeletal development. Belonging to the SP/KLF family, SP7 contains three C2H2-type zinc finger domains that mediate DNA binding. It acts downstream of RUNX2. another key osteogenic regulator, and drives the expression of bone-specific genes like osteocalcin and collagen type I. SP7 is indispensable for bone formation, as evidenced by studies showing that SP7-deficient mice exhibit complete absence of mineralized tissue and die postnatally due to skeletal defects.
Recombinant SP7 protein is typically produced using expression systems like E. coli or mammalian cell lines, enabling biochemical studies and functional characterization. Its applications span bone biology research, including investigations into osteoporosis, fracture healing, and genetic skeletal disorders. Researchers utilize recombinant SP7 to study molecular mechanisms of osteoblast commitment, its interaction with co-regulators (e.g., β-catenin), and epigenetic modifications during skeletal development.
Pharmaceutically, SP7 has emerged as a potential target for bone regenerative therapies. In tissue engineering, it supports stem cell-based strategies for bone repair. Recent studies also explore its role beyond osteogenesis, including dental formation and ectopic calcification diseases. The development of bioactive recombinant SP7 continues to advance our understanding of skeletal homeostasis and therapeutic interventions for metabolic bone diseases.
×
